LIGHT-(LINIFANIB)
Regimen
- Experimental
- linifanib 17.5 mg/day
- Control
- sorafenib
Population
Advanced hepatocellular carcinoma, no prior systemic therapy
Key finding
mOS 9.1 linifanib vs 9.8 sorafenib (HR 1.046, 95% CI 0.896-1.221); superiority/noninferiority both NOT met; linifanib higher toxicity burden (grade 3/4 AEs, SAEs, discontinuation all P<0.001 worse)
Source: PMID 25488963